Nanomedicines save lives, but they don’t reach the market or the patient’s body fast enough. Researchers have now come up with a recipe to accelerate and improve the process.
New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III – Pharmaceutical Technology
The BROOKLYN trial met its primary endpoint, achieving a mean LDL-C reduction of 36.3% compared to placebo at day 84. Credit: Shutterstock / pics five
December 10, 2024